News


Stellungnahme der DGGG empfiehlt FEMTELLE uPA PAI-1 Test

Die Deutsche Gesellschaft für Gynäkologie und Geburtshilfe veröffentlicht Stellungnahme zum Nutzen des FEMTELLE uPA PAI-1 Tests Die DGGG b... mehr...

Leitlinien empfehlen den FEMTELLE uPA/PAI-1 Test

Der uPA PAI-1 Test wird von Leitlinien auf höchstem Evidenzniveau für die klinische Anwendung empfohlen Der uPA/PAI-1 Test wird auf all... mehr...

Literatur

Auswahl an Originaliteratur


A. DEUTSCHE Literatur:

Entscheidungsfindung beim frühen Mammakarzinom. Prognostische und prädiktive Faktoren als Instrumente zur Entscheidungsfindung.
H.-C. Kolberg, M. Vetter, M. Thill, F. Marmé, P. Kern, F. Otterbach, C. Liedtke
Frauenarzt, Onkologie 2016; 7
Abstract

Mammakarzinom: Tumorbiologie-basierte Konzepte für operative und medikamentöse Therapie
Nadia Harbeck
Dtsch med Wochenschr 2013; 138(05): 180-182
Abstract

Mammakarzinom: Individualisierte Therapiekonzepte
Harbeck N. & Würstlein R. German
Internist. 2013, 54(2):194-9.
Abstract

Chemotherapie - ja oder nein?
Wissen über Tumorbiologie hilft Chemotherapie einzusparen - warum und wann der uPA/PAI-1 Test beim frühen Mammakarzinom sinnvoll ist.
Nadia Harbeck, Michael Untch, Fritz Jänicke, Christoph Thomssen
Perspektive 2010, Magazin der Frauenselbsthilfe nach Krebs e.V.
Mit freundlicher Genehmigung der Frauenselbsthilfe nach Krebs e.V. veröffentlicht
Originalarbeit

Invasionsfaktoren uPA/PAI‐1 im Tumorgewebe bei Patientinnen mit primärem Mammakarzinom: Von Forschungsergebnissen zur klinischen Anwendung am Beispiel der NNBC 3-Europe-Studie.
Vetter M, Kantelhardt EJ, Annecke K, Dittmer J, Paepke D, Prechtl A, Schmitt M, Jänicke F, Minckwitz G, Kiechle-Bahat GM, Thomssen Ch, Harbeck N
Geburtshilfe und Frauenheilkunde 2007 (67)1144-1152. German
Abstract

Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2
Mengele K, Harbeck N, Reuning U, Magdolen V, Schmitt M.
Hamostaseologie. 2005 Aug;25(3):301-10. German.
Abstract


B. ENGLISCHE Literatur (sortiert nach Erscheinungsjahr):

uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
Duffy MJ, McGowan P, Harbeck N, Thomssen C and Schmitt M.
Breast Cancer Research 2014 (16) 428.
Free PDF

Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer.
Jacobs VR, Augustin D, Wischnik A, Kiechle, Hoess C, Steinkohl O, Rack B, Kapitza T, Krase P.
Breast 2013 Aug;22(4):436-43
Abstract

Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N.
Breast Cancer Res Treat. 2013 Apr;138(3):839-50
Abstract

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C.
Eur J Cancer 2013 May;49(8):1825-35
Abstract

Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group
Daidone MG, Foekens JA, Harbeck N, Martens J, Brunner N, Thomssen C, Hall JA, Salgado R, Dittmer J, Geurts-Moespot A, Duffy MJ, Sweep FCGJ, Schmitt M, on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology Group
Eur J Cancer Supplements 2012;10(1):120-127
Abstract

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 x FEC versus 3 x FEC / 3 x Docetaxel.
Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C, Harbeck N.
BMC Cancer. 2011 Apr 16;11(1):140
Abstract

Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
Schmitt M, Harbeck N, Brünner N, Jänicke F, Meisner C, Mühlenweg B, Jansen H, Dorn J, Nitz U, Kantelhardt EJ, Thomssen C.
Expert Rev. Mol. Diagn. 2011; 11(6) 617-634
Abstract

Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N, Schmitt M.
Expert Rev Mol Diagn. 2010 Oct; 10(7):947-62.
Abstract

Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N.
Expert Rev Mol Diagn. 2010 Nov; 10(8): 1051-67.
Abstract

A new look at node-negative breast cancer.
Harbeck N, Thomssen C.
Oncologist. 2010;15 Suppl 5:29-38.
Abstract

[UPA/PAI-1: a tool for breast cancer treatment individualization. Biology, clinical implications and quantification assays].
Lamy PJ, Romieu G, Jacot W.
Bull Cancer. 2010 Mar;97(3):341-8.
Review. French.

Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens.
Thomssen C, Harbeck N, Dittmer J, Abraha-Spaeth SR, Papendick N, Paradiso A, Lisboa B, Jaenicke F, Schmitt M, Vetter M.
J. Natl. Cancer Inst. 101, 1028-1029 (2009).
Publication

Assessment of urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer tissue: historical aspects and future prospects.
Schmitt M, Mengele K, Gkazepis A, Napieralski R, Magdolen V, Reuning U, Harbeck N.
Breast Care (Basel). 3(s2), 3-10 (2008)
Publication

Prospective biomarker trials Chemo N0 and NNBC-3 Europe validate the clinical utility of invasion markers uPA and PAI-1 in node-negative breast cancer.
Harbeck N, Schmitt M, Vetter M, Krol J, Paepke D, Uhlig M, Paepke S, Jänicke F, Geurts-Moespot A, von Minckwitz G, Sweep F, Thomssen C.
Breast Care (Basel). 3(s2), 11-15 (2008).
Publication

uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.
Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C, Harbeck N.
Adv. Clin. Chem. 45, 31-45 (2008).
Abstract

Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.
Harbeck N, Schmitt M, Paepke S, Allgayer H, Kates RE.
Crit. Rev. Clin. Lab. Sci. 44, 179-201 (2007).
Abstract

Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.
Schmitt M, Sturmheit AS, Welk A, Schnelldorfer C, Harbeck N.
Methods Mol Med. 120, 245-65 (2006).
Abstract

The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ, Duggan C.
Clin Biochem. 37(7):541-8 (2004). Review.
Abstract

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomssen C, Look MP, Foekens JA.
Clin Breast Cancer. 5(5):348-52 (2004). Review.
Abstract

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.
Thromb Haemost. 91, 450-56 (2004).
Abstract

Clinical relevance of prognostic factors in axillary node-negative breast cancer.
Thomssen C, Janicke F, Harbeck N.
Onkologie. 26, 438-45 (2003).
Abstract

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Fred Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendah PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder M, Manders P, Edward Fiets W, Blankenstein M, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex L, Klijn J, O’Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens J.
Thromb Haemost. 2003 (90) 538-48.
Abstract

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Hofler H, Kiechle M, Schmitt M, Harbeck N.
J Clin Oncol. 2003 (21) 1022-8.
Abstract

Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers ind breast cancer from pilot to level I evidence studies.
Duffy MJ.
Clinical Chem 2002 (48) 1194-1197.
Abstract

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Kruger A, Kiechle M, Janicke F, Schmitt M, Foekens JA.
Cancer Res. 2002 (62) 4617-22.
PDF-Dokument

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Janicke F, Thomssen C.
Clin Breast Cancer. 2002 (3):196-200. Review.
Abstract

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Kruger A, Kiechle M, Janicke F, Schmitt M, Foekens JA.
Cancer Res. 2002 (62) 4617-22.
PDF-Dokument

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Harbeck N, Kates RE, Schmitt M.
J Clin Oncol. 2002 (20) 1000-7.
Abstract

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M;German N0 Study Group.
J Natl Cancer Inst. 2001 (93) 913-20.
Abstract

Pooled analysis of prognostic impact of uPA and PAI-1 in 8377 breast cancer patients.
Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O’Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA.
J Natl Cancer Inst 2000 (94) 116-128.
Abstract

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
Cancer Res 2000 (60) 636-643.
PDF-Dokument

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Hofler H, Janicke F, Graeff H, Schmitt M.
Breast Cancer Res. Treat 1999 (54) 147-157.
Abstract

Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
Duffy MJ, Maguire TM, McDermott EW, O’Higgins N.
J. Surg. Oncol. 1999 (71) 130-135.
Abstract

External quality assessment of trans-European multicentre antigen determinations (ELISA) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts.
Sweep CG, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJ, Schmitt M, Duffy MJ, Janicke F, Kramer MD, Foekens JA, Brunner N, Brugal G, Pedersen AN, Benraad TJ.
Br J Cancer 1998 (78) 1434-1441.
Abstract

Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy.
Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H.
Thromb Haemost 1997 (78) 285-296.
Abstract

Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H.
Cancer Research 1994 (54) 2527-2530.
Abstract

Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Janicke F, Klijn JG.
Journal of Clinical Oncology 1994 (12) 1648-1658.
Abstract

Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer.
Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H.
Breast Cancer Res. Treat. 1993 (24): 195-208.
Abstract

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M.
Cancer Research 1993 (53) 2513-2521.
Abstract


Dies ist eine Auswahl an Literaturstellen ohne Anspruch auf Vollständigkeit. Bei Rückfragen und Kommentaren zur Publikationsliste wenden Sie sich bitte an:
Dr. Claudia Olenik
email:    c.olenik@amdiag.de
tel:     +49 6157 803817



Um unsere Webseite optimal gestalten und fortlaufend verbessern zu können, verwenden wir Cookies.
Cookies sind kleine Dateien, die temporär auf Ihrer Festplatte abgelegt werden. Natürlich können Sie unsere Website auch ohne Cookies betrachten. Sie können das Speichern von Cookies auf Ihrer Festplatte verhindern, indem Sie die Browser-Einstellung "keine Cookies akzeptieren" wählen.
x